Pramipexole for Binge Eating Disorder

Status Withdrawn

Clinical Trial Summary

This study is being conducted to evaluate the effects that the drug pramipexole has on mood, food craving, and other behaviors that may be related to binge eating disorder.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01106053
Study type	Interventional
Source	Neuropsychiatric Research Institute, Fargo, North Dakota
Contact
Status	Withdrawn
Phase	Phase 3
Start date	April 2010

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02978742` - Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder	N/A
Recruiting	`NCT02659488` - Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects	Phase 2
Completed	`NCT02659475` - Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)	Phase 2
Completed	`NCT00601653` - Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder	N/A
Completed	`NCT02834299` - Dialectical Behavior Therapy Guided Self-Help for Binge Eating Disorder	N/A
Completed	`NCT02553824` - FDA Approved Medication to Reduce Binge Eating and/or Purging	Phase 1
Completed	`NCT02564588` - Dasotraline Binge Eating Disorder Study	Phase 2/Phase 3
Completed	`NCT00307190` - Hormone Release and Stomach Disturbances in People With Binge Eating Disorder	N/A
Completed	`NCT01718509` - SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder	Phase 3
Completed	`NCT01718483` - SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder	Phase 3
Completed	`NCT02503098` - Optimizing a Smartphone Application for Individuals With Eating Disorders	N/A
Active, not recruiting	`NCT01837953` - Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial	N/A
Completed	`NCT01010789` - Armodafinil in Binge Eating Disorder (BED)	Phase 3
Completed	`NCT01098435` - ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder	Phase 2
Completed	`NCT01552759` - Appetite Hormones in Binge Eating Disorder	N/A
Completed	`NCT00330655` - An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder	Phase 4
Completed	`NCT01291173` - Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder	Phase 2
Completed	`NCT03107026` - A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder	Phase 3
Completed	`NCT02079935` - Treatment of Eating Disorders by Physical Activity and Nutrition Counseling	N/A
Completed	`NCT00277641` - Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity	Phase 3